Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial).

• Tác giả: Jingxian Chen, Zhe-Sheng Chen, Feiying Deng, Yale Duan, Kaijian Hou, Zhizhen Hu, Jilin Li, Liping Li, Weiting Liu, Yu Tian, Wei Wu, Bin Xie, Wencan Xu, Haibo Xue, Shuhui Yang, Junjun Ye, Yanyan Zhao, Dan Zhu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 297.1248 Sources of Islam
• Thông tin xuất bản: China : MedComm , 2025
• Bộ sưu tập: NCBI
• ID: 57248

Tóm tắt

This study aimed to determine the effects of polyethylene glycol loxenatide (PEG-Loxe), a glucagon-like peptide-1 receptor agonist, on a three-point major adverse cardiovascular event (3P-MACE) in patients with type 2 diabetes mellitus (T2DM). The study was conducted in six tertiary hospitals in three cities in China. Large language models were used to retrospectively screen and include 12,341 patients with T2DM who had either cardiovascular disease or cardiovascular risk factors. The patients were divided into the PEG-Loxe cohort (treated with PEG-Loxe,